PUBLISHER: DataM Intelligence | PRODUCT CODE: 1289775
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1289775
The Global Heart Attack Diagnostics Market reached US$ 8,744.6 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15,605.3 million by 2030. The global heart attack diagnostics market is expected to exhibit a CAGR of 7.7% during the forecast period (2023-2030).
The global heart attack diagnostics market is influenced by a number of variables, including dietary habits, environmental exposures, and genetic susceptibility. These elements can increase the risk of cardiovascular disease by causing high blood pressure, high cholesterol, obesity, and diabetes.
Heart attacks also are greatly influenced by unhealthy habits including smoking, drinking too much alcohol, and eating a lot of fast food. The prevalence of heart attacks among the population has increased as a result of the adoption of these harmful habits.
Heart attack diagnostics market expansion is being fueled by elements including rising healthcare spending, partnerships and collaborations between leading players, and increased R&D.
For instance, in November 2022, Heartbeat Health, the nation's largest virtual-first cardiovascular company, and Cleerly, the startup developing a new standard of care for heart illness, announced a partnership to employ precision heart health to more precisely evaluate cardiovascular risk and provide better heart care. Physicians may more quickly recognize, describe, and measure atherosclerosis (plaque buildup) in the walls of heart arteries thanks to Cleerly's AI-enabled approach for analyzing coronary computed tomography angiography (CCTA).
Additionally, in November 2022, CardioSignal and OMRON Healthcare, a manufacturing and sales of automation components, equipment and systems company, joined forces to serve doctors at the forefront of population health management by delivering breakthroughs in early cardiovascular disease detection to them.
The two businesses will work together to develop digital health solutions that enhance workflow procedures for lifestyle chronic diseases, particularly for the primary care identification of cardiovascular disease. Key players' strategies serve to propel the market in such a manner.
A team of highly certified, skilled, and experienced healthcare experts is needed to carry out an efficient cardiac catheterization operation because it is a challenging treatment that demands a high level of precision and accuracy.
It is anticipated that throughout the projection period, market expansion will be somewhat constrained by a dearth of skilled specialists to perform coronary angiograms, particularly in emerging nations due to the absence of comprehensive training programs.
The SARS-CoV-2 virus epidemic led to a global lockdown and had a disastrous impact on heart attack diagnosis. People with heart conditions are more likely to develop the virus, especially those who are prone to heart attacks, and if the infection is not identified early enough, there is a high likelihood that they will die.
Additionally, there are significant worries regarding the long-term deterioration of cardiovascular health outcomes as a result of a lack of prompt diagnosis. There aren't many different parties involved in patient access to cardiovascular diagnosis and treatment.
The Russia-Ukraine is estimated to have a minimal impact on the global heart attack diagnostics market owing to the absence of key market players in this region. However, the impact of the import and export of raw materials, test products, and devices is anticipated to have little influence over the global heart attack diagnostics market in the forecast period.
Artificial intelligence is anticipated to impact the global heart attack diagnostics market positively. Because AI algorithms can analyze vast amounts of patient data, including medical records, lab results, imaging scans, and genetic information. By processing this data, AI can identify patterns and subtle indicators that may go unnoticed by human physicians, leading to more accurate and reliable diagnoses of heart attacks.
AI algorithms can analyze data in real-time, providing rapid and accurate diagnosis of heart attacks. This can be particularly useful in emergency situations where time is critical, allowing doctors to quickly begin appropriate treatment
The global heart attack diagnostics market is segmented based on test type, end-user, and region.
The electrocardiogram segment holds about 47.5% of the total heart attack diagnostics market in the forecast period. ECG gathers crucial data on the general health and performance of the heart by measuring and documenting the electrical signals the heart produces as it contracts and relaxes. Additionally, the segment is growing as a result of the leading companies' product launches and technological improvements.
For instance, in September 2020, AliveCor, a personal electrocardiogram (ECG) technology business with US FDA clearance, made its entry into the Indian market with the release of KardiaMobile 6L, a clinically-validated personal ECG device. The personal ECG device is the only six-lead, FDA-approved personal ECG device available in the world. Atrial fibrillation (AFib), bradycardia, and tachycardia, the three most prevalent arrhythmias or abnormal heartbeats, can all be found using this device.
The Europe region holds the second largest share of the global heart attack diagnostics market accounting for approximately 32.1% in the forecast period.
Due to a constant increase in the number of patients with CAD and peripheral artery disorders, the market for global heart attack diagnostics is continuously witnessing growth. According to results made available by the European Union in March 2022, heart attacks were a significant cause of fatalities in the EU.
Additionally, technical developments are enabling portable characteristics in testing equipment, supporting the expansion of the market's revenue. In order to diagnose heart attacks and raise blood levels of MyC rather than troponin to rapidly rule out the possibility of heart attacks in patients, Kings College London created a novel blood test gadget.
The major global players in the market include: F Hoffmann-La Roche Ltd, Hitachi Medical Systems, GE Healthcare, Schiller AG, Siemens Healthineers, HeartFlow, Beckman Coulter, Inc., Medtronic, Cardio Diagnostics Holdings Inc, and Midmark Corporation, among others.
The global heart attack diagnostics market report would provide approximately 53 tables,54 figures, and 195 pages.
LIST NOT EXHAUSTIVE